Cigna
Coverage of Cigna in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
An FDA advisory panel recommended Replimune's experimental melanoma drug RP1 after a 10-3 vote, but the weight loss drug market shows signs of slowing as employers and insurers reduce coverage. The FDA's new leadership is being observed for its approach to evaluating investigational drugs.
- Cigna is raising its annual profit forecast on specialty drug strength
Cigna is raising its annual profit forecast due to strength in specialty drugs. The health company now expects full-year adjusted earnings of at least $30.45 per share, an increase of 10 cents from its previous outlook.
- Sixth Circuit won’t compel RFK Jr. to enforce nondiscrimination provision of ACA
The Sixth Circuit declined to force the federal government to enforce the Affordable Care Act's nondiscrimination provision against private insurers paying nurse anesthetists less than doctors for the same services. The American Association of Nurse Anesthesiology sued the U.S. Department of Health and Human Services, arguing insurers' disparate compensation violates the ACA, but the court found the association lacked standing because the harm stemmed from insurers, not HHS.
- How a marathon-running CEO set the pace for Cigna
David Cordani is stepping down as Cigna CEO after 17 years, during which the company's revenue grew from $18 billion to $275 billion. He attributed the recent public distrust in health insurers to rising healthcare costs and responded by launching Cigna's 'Commitments to Better' initiative to rebuild trust. The December 2024 shooting of UnitedHealthcare CEO Brian Thompson heightened industry tensions, prompting Cigna to prioritize active listening to address societal concerns.
- STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
Cigna will stop covering GLP-1 weight loss drugs like Wegovy and Zepbound in its employee health plan starting July 1, directing users to cash-pay options. A study suggests long-term use of GLP-1 drugs could reduce knee replacement risk by up to 5% over eight years. Prices for these drugs are declining in 2026 with new oral versions.
- Arizona sues MultiPlan, major insurers, alleging a ‘cartel’ that underpaid doctors and hospitals
Arizona Attorney General Kris Mayes filed a lawsuit against MultiPlan (now Claritev) and major insurers like Aetna, Cigna, and UnitedHealthcare, alleging they colluded to use a proprietary algorithm to set lower rates for out-of-network care, underpaying providers and shifting costs to patients. The lawsuit claims this violated Arizona’s anti-trust and consumer fraud laws, while MultiPlan denied the allegations, stating the case is 'without merit.'
- Former Memphis school board member, local lawyer tapped for new schools oversight board
Billy Orgel and Dedrick Brittenum Jr. have been appointed to a state-led oversight board overseeing Memphis-Shelby County Schools. The board, which will control key district decisions until 2030, includes members from various professional backgrounds, including business, law, and education.
- "Not Medically Necessary": Helping America's Health Insurers Deny Coverage
The article discusses health insurance denials in America, specifically the practice of requiring prior authorizations. Major health insurers such as Cigna, UnitedHealthcare, and Aetna are mentioned. The article highlights the issue of denying coverage for treatments deemed not medically necessary.
- Cigna’s exit adds to ObamaCare marketplace upheaval
Cigna is exiting the Affordable Care Act (ACA) exchanges by 2027, exacerbating instability in the individual health insurance marketplace following the loss of enhanced federal subsidies. The company reported a strong first-quarter financial performance despite the decision.